【ChiCTR2000029649】Recurrence and satisfaction with sutured surgical treatment of an ingrown toenail with nail and matrix preservation
ChiCTR2000029649
结束
/
/
/
2020-02-09
/
/
ingrown toenail
Recurrence and satisfaction with sutured surgical treatment of an ingrown toenail with nail and matrix preservation
Recurrence and satisfaction with sutured surgical treatment of an ingrown toenail with nail and matrix preservation
61-545
Techniques with the preservation of the nail and matrix are not often used. We have found that the nail plate itself is a good point for skin plasty. We were interested in whether a satisfactory result could be obtained without removal or partial resection of the nail plate, i.e. with only soft tissue resection and skin plasty. Our goal was to evaluate the results of ingrown nail corrections in patients who underwent our surgical approach in terms of healing time, pain relief, relapse and scarring.
单臂
回顾性研究
no
/
no sponsor
/
40
/
2017-07-10
2019-08-12
/
Participants in the study were included if they were children, adolescents or adults who decided to undergo our procedure with preservation of the nail and matrix for one or more ingrown toenails.；
请登录查看Individuals were excluded if they could not understand Polish or had significant medical comorbidities.；
请登录查看Mikolaj Dabrowski
61-545
Mikolaj Dabrowski的其他临床试验
波兰波茲南医科大学脊柱矫形与生物力学系的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04